Search Results - "Untch, Brian R"

ATRX, DAXX or MEN1 mutant pancreatic neuroendocrine tumors are a distinct alpha-cell signature subgroup by Chan, Chang S., Laddha, Saurabh V., Lewis, Peter W., Koletsky, Matthew S., Robzyk, Kenneth, Da Silva, Edaise, Torres, Paula J., Untch, Brian R., Li, Janet, Bose, Promita, Chan, Timothy A., Klimstra, David S., Allis, C. David, Tang, Laura H.

“…The commonly mutated genes in pancreatic neuroendocrine tumors (PanNETs) are ATRX , DAXX , and MEN1 . We genotyped 64 PanNETs and found 58% carry ATRX , DAXX ,…”
Get full text

Clinical sequencing of soft tissue and bone sarcomas delineates diverse genomic landscapes and potential therapeutic targets by Nacev, Benjamin A., Sanchez-Vega, Francisco, Smith, Shaleigh A., Antonescu, Cristina R., Rosenbaum, Evan, Shi, Hongyu, Tang, Cerise, Socci, Nicholas D., Rana, Satshil, Gularte-Mérida, Rodrigo, Zehir, Ahmet, Gounder, Mrinal M., Bowler, Timothy G., Luthra, Anisha, Jadeja, Bhumika, Okada, Azusa, Strong, Jonathan A., Stoller, Jake, Chan, Jason E., Chi, Ping, D’Angelo, Sandra P., Dickson, Mark A., Kelly, Ciara M., Keohan, Mary Louise, Movva, Sujana, Thornton, Katherine, Meyers, Paul A., Wexler, Leonard H., Slotkin, Emily K., Glade Bender, Julia L., Shukla, Neerav N., Hensley, Martee L., Healey, John H., La Quaglia, Michael P., Alektiar, Kaled M., Crago, Aimee M., Yoon, Sam S., Untch, Brian R., Chiang, Sarah, Agaram, Narasimhan P., Hameed, Meera R., Berger, Michael F., Solit, David B., Schultz, Nikolaus, Ladanyi, Marc, Singer, Samuel, Tap, William D.

“…The genetic, biologic, and clinical heterogeneity of sarcomas poses a challenge for the identification of therapeutic targets, clinical research, and advancing…”
Get full text

International Medullary Thyroid Carcinoma Grading System: A Validated Grading System for Medullary Thyroid Carcinoma by Xu, Bin, Fuchs, Talia L, Ahmadi, Sara, Alghamdi, Mohammed, Alzumaili, Bayan, Bani, Mohamed-Amine, Baudin, Eric, Chou, Angela, De Leo, Antonio, Fagin, James A, Ganly, Ian, Glover, Anthony, Hartl, Dana, Kanaan, Christina, Khneisser, Pierre, Najdawi, Fedaa, Nigam, Aradhya, Papachristos, Alex, Repaci, Andrea, Spanheimer, Philip M, Solaroli, Erica, Untch, Brian R, Barletta, Justine A, Tallini, Giovanni, Al Ghuzlan, Abir, Gill, Anthony J, Ghossein, Ronald A

“…Medullary thyroid carcinoma (MTC) is an aggressive neuroendocrine tumor (NET) arising from the calcitonin-producing C cells. Unlike other NETs, there is no…”
Get full text

Observation versus Resection for Small Asymptomatic Pancreatic Neuroendocrine Tumors: A Matched Case–Control Study by Sadot, Eran, Reidy-Lagunes, Diane L., Tang, Laura H., Do, Richard Kinh Gian, Gonen, Mithat, D’Angelica, Michael I., DeMatteo, Ronald P., Kingham, T. Peter, Koerkamp, Bas Groot, Untch, Brian R., Brennan, Murray F., Jarnagin, William R., Allen, Peter J.

“…Objective To analyze the natural history of small asymptomatic pancreatic neuroendocrine tumors (PanNET) and to present a matched comparison between groups who…”
Get full text

Tipifarnib Inhibits HRAS-Driven Dedifferentiated Thyroid Cancers by Untch, Brian R, Dos Anjos, Vanessa, Garcia-Rendueles, Maria E R, Knauf, Jeffrey A, Krishnamoorthy, Gnana P, Saqcena, Mahesh, Bhanot, Umeshkumar K, Socci, Nicholas D, Ho, Alan L, Ghossein, Ronald, Fagin, James A

“…Of the three RAS oncoproteins, only HRAS is delocalized and inactivated by farnesyltransferase inhibitors (FTI), an approach yet to be exploited clinically. In…”
Get full text

Tumor Grade Predicts for Calcitonin Doubling Times and Disease-Specific Outcomes After Resection of Medullary Thyroid Carcinoma by Nigam, Aradhya, Xu, Bin, Spanheimer, Philip M, Ganly, Ian, Tuttle, R Michael, Wong, Richard J, Shaha, Ashok R, Ghossein, Ronald A, Untch, Brian R

“…Tumor grade is a new validated prognostic factor for medullary thyroid cancer (MTC). Calcitonin doubling time can predict MTC recurrence. We aimed to describe…”
Get more information

NF2 Loss Promotes Oncogenic RAS-Induced Thyroid Cancers via YAP-Dependent Transactivation of RAS Proteins and Sensitizes Them to MEK Inhibition by Garcia-Rendueles, Maria E R, Ricarte-Filho, Julio C, Untch, Brian R, Landa, Iňigo, Knauf, Jeffrey A, Voza, Francesca, Smith, Vicki E, Ganly, Ian, Taylor, Barry S, Persaud, Yogindra, Oler, Gisele, Fang, Yuqiang, Jhanwar, Suresh C, Viale, Agnes, Heguy, Adriana, Huberman, Kety H, Giancotti, Filippo, Ghossein, Ronald, Fagin, James A

“…Ch22q LOH is preferentially associated with RAS mutations in papillary and in poorly differentiated thyroid cancer (PDTC). The 22q tumor suppressor NF2,…”
Get more information

Surgeon-Performed Ultrasound Is Superior to 99Tc-Sestamibi Scanning to Localize Parathyroid Adenomas in Patients with Primary Hyperparathyroidism: Results in 516 Patients over 10 Years by Untch, Brian R., MD, Adam, Mohamed Abdelgadir, MD, Scheri, Randall P., MD, FACS, Bennett, Kyla M., MD, Dixit, Darshana, MA, Webb, Cynthia, BA, Leight, George S., MD, FACS, Olson, John A., MD, PhD, FACS

“…Background Surgeon-performed cervical ultrasound (SUS) and 99Tc-sestamibi scanning (MIBI) are both useful in patients with primary hyperparathyroidism (PHPT)…”
Get full text

ASO Author Reflections: Morbidity and Outcomes of Primary Tumor Management in Patients with Widely Metastatic Well-Differentiated Small Bowel Neuroendocrine Tumors by Nigam, Aradhya, Untch, Brian R.

Get full text

Well-Differentiated Neuroendocrine Tumors with a Morphologically Apparent High-Grade Component: A Pathway Distinct from Poorly Differentiated Neuroendocrine Carcinomas by Tang, Laura H, Untch, Brian R, Reidy, Diane L, O'Reilly, Eileen, Dhall, Deepti, Jih, Lily, Basturk, Olca, Allen, Peter J, Klimstra, David S

“…Most well-differentiated neuroendocrine tumors (WD-NET) of the enteropancreatic system are low-intermediate grade (G1, G2). Elevated proliferation demonstrated…”
Get full text

PD-1 Blockade in Advanced Adrenocortical Carcinoma by Raj, Nitya, Zheng, Youyun, Kelly, Virginia, Katz, Seth S, Chou, Joanne, Do, Richard K G, Capanu, Marinela, Zamarin, Dmitriy, Saltz, Leonard B, Ariyan, Charlotte E, Untch, Brian R, O'Reilly, Eileen M, Gopalan, Anuradha, Berger, Michael F, Olino, Kelly, Segal, Neil H, Reidy-Lagunes, Diane L

“…Adrenocortical carcinomas (ACC) are rare and aggressive malignancies with limited treatment options. This study was undertaken to evaluate the immunogenicity…”
Get full text

Impact of 25-Hydroxyvitamin D Deficiency on Perioperative Parathyroid Hormone Kinetics and Results in Patients with Primary Hyperparathyroidism by Untch, Brian R., MD, Barfield, Michael E., BS, Dar, Moahad, MD, Dixit, Darshana, MS, Leight, George S., MD, Olson, John A., MD, PhD

“…Background Successful parathyroidectomy for sporadic primary hyperparathyroidism (pHPT) is predicted by a 50% drop in PTH intra-operatively. Vitamin D is a…”
Get full text

The Surgical Management of Small Bowel Neuroendocrine Tumors: Consensus Guidelines of the North American Neuroendocrine Tumor Society by Howe, James R, Cardona, Kenneth, Fraker, Douglas L, Kebebew, Electron, Untch, Brian R, Wang, Yi-Zarn, Law, Calvin H, Liu, Eric H, Kim, Michelle K, Menda, Yusuf, Morse, Brian G, Bergsland, Emily K, Strosberg, Jonathan R, Nakakura, Eric K, Pommier, Rodney F

“…Small bowel neuroendocrine tumors (SBNETs) have been increasing in frequency over the past decades, and are now the most common type of small bowel tumor…”
Get full text

Treatment Response and Outcomes of Grade 3 Pancreatic Neuroendocrine Neoplasms Based on Morphology: Well Differentiated Versus Poorly Differentiated by Raj, Nitya, Valentino, Emily, Capanu, Marinela, Tang, Laura H, Basturk, Olca, Untch, Brian R, Allen, Peter J, Klimstra, David S, Reidy-Lagunes, Diane

“…Emerging data suggest that not all grade 3 (G3) pancreatic neuroendocrine neoplasms (panNENs) behave the same; tumor differentiation may predict outcome…”
Get full text

Grading of medullary thyroid carcinoma on the basis of tumor necrosis and high mitotic rate is an independent predictor of poor outcome by Alzumaili, Bayan, Xu, Bin, Spanheimer, Philip M., Tuttle, R. Michael, Sherman, Eric, Katabi, Nora, Dogan, Snjezana, Ganly, Ian, Untch, Brian R., Ghossein, Ronald A.

“…Medullary thyroid carcinoma (MTC) is a rare nonfollicular cell-derived tumor. A robust grading system may help better stratify patients at risk for recurrence…”
Get full text

Integrative Genomic Characterization Identifies Molecular Subtypes of Lung Carcinoids by Laddha, Saurabh V, da Silva, Edaise M, Robzyk, Kenneth, Untch, Brian R, Ke, Hua, Rekhtman, Natasha, Poirier, John T, Travis, William D, Tang, Laura H, Chan, Chang S

“…Lung carcinoids (LC) are rare and slow growing primary lung neuroendocrine tumors. We performed targeted exome sequencing, mRNA sequencing, and DNA methylation…”
Get full text

Prophylactic Lateral Neck Dissection for Medullary Thyroid Carcinoma is not Associated with Improved Survival by Spanheimer, Philip M., Ganly, Ian, Chou, Joanne F., Capanu, Marinela, Nigam, Aradhya, Ghossein, Ronald A., Tuttle, R. Michael, Wong, Richard J., Shaha, Ashok R., Brennan, Murray F., Untch, Brian R.

“…Background Patients with medullary thyroid carcinoma (MTC) often receive lateral lymph node dissection with total thyroidectomy when calcitonin levels are…”
Get full text

Cooperative genomic lesions in HRAS-mutant cancers predict resistance to farnesyltransferase inhibitors by Nigam, Aradhya, Krishnamoorthy, Gnana P., Chatila, Walid K., Berman, Katherine, Saqcena, Mahesh, Walch, Henry, Venkatramani, Mandakini, Ho, Alan L., Schultz, Nikolaus, Fagin, James A., Untch, Brian R.

“…In the clinical development of farnesyltransferase inhibitors (FTIs) for HRAS -mutant tumors, responses varied by cancer type. Co-occurring mutations may…”
Get full text

Morbidity and Outcomes of Primary Tumor Management in Patients with Widely Metastatic Well-Differentiated Small Bowel Neuroendocrine Tumors by Nigam, Aradhya, Li, Janet W. Y., Fiasconaro, Megan, Lin, Sabrina, Capanu, Marinela, Kleiman, David A., Memeh, Kelvin, Raj, Nitya, Reidy-Lagunes, Diane L., Untch, Brian R.

“…Background The benefit of primary tumor resection in distant metastatic small bowel neuroendocrine tumors (SBNETs) is controversial, with treatment-based…”
Get full text

FGFR2::TACC2 fusion as a novel KIT‐independent mechanism of targeted therapy failure in a multidrug‐resistant gastrointestinal stromal tumor by Dermawan, Josephine K., Vanderbilt, Chad M., Chang, Jason C., Untch, Brian R., Singer, Samuel, Chi, Ping, Tap, William D., Antonescu, Cristina R.

“…Genetic alterations in FGF/FGFR pathway are infrequent in gastrointestinal stromal tumors (GIST), with rare cases of quadruple wildtype GISTs harboring FGFR1…”
Get full text